We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
DOPTELET (Swedish Orphan Biovitrum Pty Ltd)
Product name
DOPTELET
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
248 (255 working days)
Active ingredients
avatrombopag maleate
Registration type
NCE/NBE
Indication
DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.